The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome

Gynecological Endocrinology

Volumn 21, Issue 3, 2005, Pages 154-160

  Yilmaz, Murat ^a,c   Karakoç, Ayhan ^b   Törüner, Füsun B ^b   Çakir, Nuri ^b   Tiras, Bülent ^b   Ayvaz, Göksun ^b   Arslan, Metin ^b  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Hirsutism; Menstrual cyclicity; Metformin; Polycystic ovary syndrome; Rosiglitazone

Indexed keywords

ANDROSTENEDIONE; FOLLITROPIN; GLUCOSE; INSULIN; LUTEINIZING HORMONE; METFORMIN; PRASTERONE SULFATE; ROSIGLITAZONE; SEX HORMONE; TESTOSTERONE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HEADACHE; HIP; HIRSUTISM; HUMAN; INSULIN BLOOD LEVEL; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUATION; MENSTRUATION DISORDER; NAUSEA; ORAL GLUCOSE TOLERANCE TEST; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STOMACH PAIN; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; VOMITING;

ADULT; ANDROSTENEDIONE; FEMALE; GLUCOSE TOLERANCE TEST; HIRSUTISM; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MENSTRUAL CYCLE; METFORMIN; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 27744468626     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500231627     Document Type: Article

References (44)

1. Frank S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-861.
2. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-1880.
3. Dunaif A, Segal K, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
4. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
5. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-579.
6. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004;82:893-902.
7. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004;82:421-429.
8. La Marca A, Egbe TO, Morgante G, Paglia T, Cianci A, De Leo V, Ciani A. Metformin treatment reduces ovarian cytochrome P-450c17 response to human chorionic gonadotropin in women with insulin resistance-related polycystic ovary syndrome. Hum Reprod 2000;15:21-23.
9. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-146.
10. Morin-Papunen LC, Koivunen RM, Ruokonene A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998;69:691-696.
11. Unluhizarci K, Kelestimur F, Bayram F, Sahin Y, Tutus A. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1999;51:231-236.
12. Kolodziecjzyk B, Dubela AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenizm and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000;73:1149-1154.
13. Vandermolen DT, Parts VS, Evans WS. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001;75:310-315.
14. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Satar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002;87:569-574.
15. Kocak M, Caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 2002;77:101-106.
16. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:524-529.
17. Goldstein BJ. Current views on the mechanisms of action of thiazolidinedione insulin sensitizers. Diabetes Technol Ther 1999;1:267-275.
18. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke EW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003;79:562-566.
19. Belli S, Graffigma M, Oneto A, Otero P, Schurman L, Levalle O. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 2004;81:624-629.
20. Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig 2003;10:99-104.
21. Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance J Clin Endocrinol Metab 2005;90:60-65.
22. Cataldo N, Abassi F, McLaughlin T, Lamendola C, Reaven G. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil Steril 2001;75:1057-1059.
23. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-2574.
24. Gania MA, Khurana ML, Eunice M, Gulati M, Dwivedi SN, Amini AC. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab 2004;89:2756-2762.
25. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000;85:3161-3168.
26. Kriplani A, Agarwal N. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. Reprod Med 2004;49:361-367.
27. Harborne L, Fleming R, Lyall H, Satar N, Norman J. Metformin and antiandrogen treatment in the treatment of polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4216-4223.
28. Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol 2003;17:51-56.
29. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626-1632.
30. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;81:19-25.
31. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
32. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, et al., The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-3167.
33. Franks S, Gilling-Smith C, Watson H, Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 1999;28:361-378.
34. Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994;79:1158-1165.
35. Cara JF, Fan J, Azzarello J, Rosenfield RL. Insulin-like growth factor I enhances luteinizing hormone binding to rat ovarian theca-interstitial cells. J Clin Invest 1990;86:560-565.
36. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83-89.
37. Kelestimur F, Sahin Y. Alternate pathway 17,20-lyase enzyme activity in the adrenals is enhanced in patients with polycystic ovary syndrome. Fertil Steril 1999;71:1075-1078.
38. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2694-2698.
39. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
40. Bulgan Kilicdag E, Bagis T, Zeyneloglu HB, Tarim E, Asian E, Haydardedeoglu B, Erkanli S. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 2004;23:1-6.
41. Azziz R, Ehrman D, Legro RS, Fereshetian AG, O'Keefe M, Ghazzi MN. Troglitazone decreases adrenal androgen levels in woman with polycystic ovary syndrome. Fertil Steril 2003;79:932-937.
42. Arlt W, Auchus RJ, Miller W. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3β-hydroxysteroid dehydrogenase. J Biol Chem 2001;276:16767-16771.
43. D. Duplay. Avandia Product Information (White pages) Physicians Desk References. New Jersey: Thomson PDR. pp 401-3534.
44. Coetzee EJ, Jackson WPU. Metformin in management of pregnant insulin-independent diabetics. Diabetologia 1979;16:241-245.